Danazol Therapy in Acquired Idiopathic Sideroblastic Anemia
article
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This study evaluated danazol therapy in six patients with acquired idiopathic sideroblastic anemia, finding no improvement in hemoglobin or platelet counts in any participant.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Danazol, a synthetic androgen, was used in the treatment of 6 patients with acquired idiopathic sideroblastic anemia. No patient had a response to therapy as determined by an increase in either the hemoglobin or platelet count.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (6)
- Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review 2023
- Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review 2023
- Danazol in Idiopathic Sideroblastic Anemia 2009
- Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone 2000
- Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases 1994
- Therapeutic efficacy of danazol in myelodysplastic syndromes 1988
Source provenance
- openalex
- last seen: 2026-05-13T18:27:55.367740+00:00
License: CC0
· commercial use OK